<DOC>
	<DOC>NCT01557127</DOC>
	<brief_summary>This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.</brief_summary>
	<brief_title>Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Age &gt;/= 18 years Diagnosis of renal cell carcinoma Failure of prior therapy with interferonalfa (IFN) or interleukine2 (IL2) or disqualified from therapy with IFN/IL2 Patients in whom the oncologist has decide to start therapy with sorafenib. Synonymous with contraindications to Nexavar.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Renal cell carcinoma,</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Dosing</keyword>
</DOC>